pcDNA3.3_CoV1_D28 Citations (8)

Originally described in: Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G, Woehl J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng L, Ramirez S, Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee D, Teijaro JR, Voss JE, Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG, Burton DR Science. 2020 Aug 21;369(6506):956-963. doi: 10.1126/science.abc7520. Epub 2020 Jun 15. PubMed Journal

---

Articles Citing pcDNA3.3_CoV1_D28

Articles
LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans. Song J, Chow RD, Pena-Hernandez M, Zhang L, Loeb SA, So EY, Liang OD, Wilen CB, Lee S. bioRxiv. 2021 Nov 24. doi: 10.1101/2021.11.23.469714. PubMed
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies. Hanke L, Sheward DJ, Pankow A, Vidakovics LP, Karl V, Kim C, Urgard E, Smith NL, Astorga-Wells J, Ekstrom S, Coquet JM, McInerney GM, Murrell B. Sci Adv. 2022 Mar 25;8(12):eabm0220. doi: 10.1126/sciadv.abm0220. Epub 2022 Mar 25. PubMed Associated Plasmids pHEN-CoV2-nanobody-G6 pHEN-CoV2-nanobody-E2 pHEN-CoV2-nanobody-C7 pHEN-CoV2-nanobody-F1
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. Andreano E, Paciello I, Marchese S, Donnici L, Pierleoni G, Piccini G, Manganaro N, Pantano E, Abbiento V, Pileri P, Benincasa L, Giglioli G, Leonardi M, Maes P, De Santi C, Sala C, Montomoli E, De Francesco R, Rappuoli R. Nat Commun. 2022 Jun 13;13(1):3375. doi: 10.1038/s41467-022-31115-8. PubMed
An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif. Fang Y, Sun P, Xie X, Du M, Du F, Ye J, Kalveram BK, Plante JA, Plante KS, Li B, Bai XC, Shi PY, Chen ZJ. Sci Immunol. 2022 Oct 28;7(76):eabp9962. doi: 10.1126/sciimmunol.abp9962. Epub 2022 Oct 28. PubMed
LRRC15 inhibits SARS-CoV-2 cellular entry in trans. Song J, Chow RD, Pena-Hernandez MA, Zhang L, Loeb SA, So EY, Liang OD, Ren P, Chen S, Wilen CB, Lee S. PLoS Biol. 2022 Oct 13;20(10):e3001805. doi: 10.1371/journal.pbio.3001805. eCollection 2022 Oct. PubMed
Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. Dacon C, Peng L, Lin TH, Tucker C, Lee CD, Cong Y, Wang L, Purser L, Cooper AJR, Williams JK, Pyo CW, Yuan M, Kosik I, Hu Z, Zhao M, Mohan D, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Murphy M, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Doranz BJ, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Mascola JR, Holbrook MR, Nemazee D, Wilson IA, Tan J. Cell Host Microbe. 2022 Nov 4. pii: S1931-3128(22)00523-6. doi: 10.1016/j.chom.2022.10.010. PubMed Associated Plasmids pcDNA3.3_SARS2_omicron_BA.2.75
B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response. Andreano E, Paciello I, Pierleoni G, Piccini G, Abbiento V, Antonelli G, Pileri P, Manganaro N, Pantano E, Maccari G, Marchese S, Donnici L, Benincasa L, Giglioli G, Leonardi M, De Santi C, Fabbiani M, Rancan I, Tumbarello M, Montagnani F, Sala C, Medini D, De Francesco R, Montomoli E, Rappuoli R. Nat Commun. 2023 Jan 4;14(1):53. doi: 10.1038/s41467-022-35781-6. PubMed
Antiviral activity of marine sulfated glycans against pathogenic human coronaviruses. Zoepfl M, Dwivedi R, Kim SB, McVoy MA, Pomin VH. Sci Rep. 2023 Mar 23;13(1):4804. doi: 10.1038/s41598-023-31722-5. PubMed

If you have published an article using this material, please email us at to have your article added to this page.